Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Mass Gen's Dr. Ali Raja explains why some were sent to the emergency room after using semaglutide injections. Raja says some of the symptoms people experienced won't require an ER visit. Raja says not ...

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...